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mated, where EQ-5D was regressed on 1) eight SF-36 scores; 2) as per 1) plus squared 
and pair-wise interaction terms, 3) as per 1) plus clinical characteristics; and 4) as 
per 3) plus squared and pair-wise interaction terms, respectively. Model 2 and 4 were 
developed by using stepwise regression analyses. Model goodness of fit was examined 
by using Akaike information criterion (AIC), R2, and adjusted R2. Predictive perfor-
mance was evaluated by using root mean square error (RMSE). Results: Model 1 with 
eight SF-36 scores explained more than 59% of the variation in EQ-5D utility values. 
The best-performing model based on goodness of fit and predictive performance was 
model 4 (AIC= ◽-200.4, R2= 0.767, adjusted R2= 0.709, RMSE= 0.090). The model included 
four SF-36 scores (GH, MH, PF, and RP), five squared terms, twelve pair-wise interaction 
terms, and log transformed simplified disease activity index (SDAI). Also model 2, 
which included no clinical characteristics, had similar predictive ability (AIC= ◽-195.0, 
R2= 0.764, adjusted R2= 0.699, RMSE= 0.093). ConClusions: EQ-5D utility values can be 
predicted from SF-36 scores and SDAI with Japanese patients with RA. The mapping 
model can be applied to SF-36 datasets to produce utility scores for economic evalua-
tion of RA treatments from the perspective of Japan health care system.
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objeCtives: Rheumatoid arthritis is (RA) associated with numerous comorbidities 
that have major impacts on patients’ quality of life. The purpose of this study is 
of twofold, first, to measure the health related utilities on patients with RA using 
time trade-off (TTO) and EQ-5D and to examine how these different measures were 
related to a disease specific measure, Health Assessment Questionnaire (HAQ) and 
disability level of RA. Second, to investigate absenteeism and presenteeism using 
Work Productivity and Activity Impairment Questionnaire for Patients with RA 
(WPAI-RA). Methods: Face-to-face patient interviews on patients with mild RA 
(DAS < 3.2), moderate RA (3.2< = DAS< 5.1) and severe RA (DAS> = 5.1) have been car-
ried out since June 2013 at rheumatology outpatient clinics at four hospitals located 
in northern, central and southern Taiwan, and will be continued until the desired 
sample size of 120 is attained. Health state utilities were elicited using time trade-
off (TTO), visual analogue scale (VAS) and EQ-5D. Productivity losses and activity 
limitation were measured by WPAI-RA. The mean value of the total HAQ score is 
the mean of the scores for the eight categories: dressing, rising, eating, walking, 
hygiene, reach, grip and usual activities. Results: Based upon the preliminary 
sample collected, the mean age was 54.5 years, mean history of disease was 8.16 
years, and 77% were female in the study patients. The mean health utility was 0.87 
(EQ-5D), 0.72 (VAS) and 0.75 (TTO). The mean value of the total HAQ score is 0.83. 
Employed patients reported 10% reduced work productivity in the previous week, as 
well as 21.0% reduced productivity in daily activities (all patients). ConClusions: 
EQ-5D and VAS are consistent measures for HAQ and have high potentials for use 
in assessing the well-being of the patients with RA in Taiwan. Productivity losses 
associated with absenteeism and presenteeism are substantial.
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objeCtives: For patients with rheumatoid arthritis (RA), convenience, frequency 
of dosing, and invasiveness vary greatly across different administration routes and 
may influence their everyday lives. The objective of this study was to investigate 
the impact of administration method on patients’ quality of life, understand their 
resulting unmet needs, and establish an overall preference for method of admin-
istration for RA treatment. Methods: Patients from France, UK, Germany, Italy, 
Spain, Belgium, Sweden, and The Netherlands diagnosed with RA by a physician and 
taking prescription medication – disease-modifying anti-rheumatic drug (DMARD) 
monotherapy, biologic monotherapy, or DMARD and biologic combination therapy 
– completed a 20-minute online survey. Patients were asked about: 1) benefits and 
drawbacks of their current treatment administration method; 2) their preference 
for twice-daily oral therapy versus injection or intravenous (IV) infusion therapy if it 
met their safety and efficacy expectations; 3) if told by their doctor that they needed 
to change their current RA therapy, would they switch to twice-daily oral tablets, 
injections, or IV infusion if efficacy and safety requirements were met. Results: 
1400 patients were included: n= 250 patients in each of France, UK, Germany, Italy, 
and Spain and n= 50 in each of Sweden, Belgium, and The Netherlands. Oral DMARDs 
were seen as having more benefits and fewer drawbacks than DMARD injections, 
biologic injections, and IV therapy. The majority of patients (79%) would prefer a 
twice-daily oral tablet than an injection or IV infusion (21%) if it met efficacy and 
safety expectations. If told by their doctor that they needed to change their current 
RA therapy, 83% of all patients would prefer switching to twice-daily oral tablets over 
injection (13%) or IV infusion (4%). ConClusions: Oral therapy can meet some of 
the key practical and emotional unmet needs RA patients face with injectable or IV 
infusion therapy, providing efficacy and safety requirements are met.
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half-yearly or yearly) (78%) versus oral (daily, weekly, or monthly) drugs (35%). The 
lowest compliance was observed with daily (24%) and monthly (34%) drugs. Less 
frequently administered drugs (except yearly) had the highest compliance with 
quarterly drugs having 63% and half-yearly drugs 70%. ConClusions: This analy-
sis shows that persistence and compliance to osteoporosis treatment is very low 
in postmenopausal women in Hungary. However, higher persistence and better 
compliance was observed for injectable, less frequently administered drugs, which 
may lead to better outcomes.
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objeCtives: The OS-MMAS is a disease-specific 8 item self-reported measure of 
adherence for osteoporosis patients. This study evaluated the measurement prop-
erties of its French translated version. Methods: A cohort of women aged 55 or 
older, with post-menopausal osteoporosis (PMO) residing in France and treated with 
daily or weekly oral bisphosphonates (OBPs) were selected based on their historical 
data from the French Longitudinal Patient Database; following their visit to one of 
the participating practices. Eligible patients were given an OS-MMAS questionnaire 
for completion at home. Internal consistency was evaluated using the Cronbach’s 
coefficient and construct validity using confirmatory one factor analysis (CFA). 
Convergence validity was assessed using agreement between patients’ medication 
procession ratio (MPR) and their total score from OS-MMAS. To assess reproducibility, 
a subset of respondents received a second questionnaire approximately 3 months 
later. Reproducibility was tested using the intra-class correlation (ICC). Results: 
From a network of 1200 French general practices, 117 participated; 687 eligible 
women visited these practices during the period 20-Jul-2012 to 31-Dec-2012. Of 
these women, 218 (mean 73.2 years; SD= 8.1) completed ≥ 1 OS-MMAS. The 6 and 
12 month MPR was less than 80% for 25.7% patients and 59.1% patients, respec-
tively. Cronbach’s alpha coefficient was 0.76 and varied between 0.71 and 0.79 with 
the deletion of one item. The Chi-Square test of association between MPR (< 80%, 
> 80%) and OS-MMAS scores (< 6; 6-8; 8+) was statistically significant at 6 months 
(p= 0.025), but not at 12 months (p-value= 0.059). CFA reported a standardized root 
mean square residual of 0.06. The ICC on 70 patients was 0.24 with 95% confidence 
interval [0.01-0.45]. ConClusions: This study demonstrated acceptable agreement 
between classification of patient’s adherence to OBPs assessed using French trans-
lated OS-MMAS and that using historical 6 months MPR; but also indicated that the 
construct of the OS-MMAS could be improved.
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objeCtives: To obtain a comprehensive overview of the impact of TNF-inhibitors on 
the components of the burden of Rheumatoid Arthritis (RA) in Germany. Methods: 
A systematic literature research in EMBASE, Medline, grey literature including rheu-
matology congress abstracts (ACR, EULAR, DGRh), German RA registry homepages, 
and the Information System of the Federal Health Monitoring (2002-2012) was per-
formed. Published data on the effect of TNF-inhibitors on mortality, morbidity, and 
health care resource utilization (HCRU) was included. Results: Overall, 15 partially 
overlapping full-text articles (0 mortality, 12 morbidity, 5 HCRU), 6 additional unique 
abstracts excluding encore publications (1 mortality, 4 morbidity, 1 HCRU) and two 
other sources (1 morbidity, 1 HCRU) were included in the final review. Reviewed lit-
erature reported an association of TNF-inhibitor use with a 35% lower mortality rate 
(HR= 0.65; p= 0.0004) compared to synthetic disease modifying antirheumatic drugs 
(DMARDs). Disease severity based on symptoms decreased over time in Germany: the 
chances of reaching DAS28 remission (OR= 1.97; 95%-CI: [1.20-3.21]) and functional 
remission (OR= 2.21; 95%-CI: [1.06-4.63]) were doubled, the odds of functional independ-
ence were quadrupled (OR= 4.09; 95%-CI: [1.80-9.29]) with TNF-inhibitor treatment. 
All SF-36 domains and fatigue scores increased significantly after treatment initia-
tion. TNF-inhibitor treatment is associated with fewer limitations in daily activities 
(OR= 0.77; 95%-CI: [0.65-0.90] and less perseverant limitations (OR= 0.82; 95%-CI: [0.68-
0.98]. Standardized disability pension ratios in patients with biologics use decreased 
over time from 12.5 (2001–2003) to 3.4 (2010-2011). Frequency and average duration of 
hospitalization have fallen from 2001 (19% of patients hospitalized with average dura-
tion of 19 days) to 2011 (12%, 12 days). No HRCU data was available for the outpatient 
sector or surgery. ConClusions: Based on available German data, treatment with 
TNF-inhibitors is associated with lower mortality, increasing likelihood to reach clinical 
remission, better symptom control, functional status, work ability and quality of life.
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objeCtives: To develop a mapping model for estimating EuroQol 5D (EQ-5D) utility 
values from Short Form 36 (SF-36) scores in Japanese patients with rheumatoid arthri-
tis (RA), with or without clinical characteristics. Methods: Linear regression models 
were applied to a cross-sectional data set of 112 patients with RA collected from a 
regional hospital in Niigata prefecture, Japan. Four model specifications were esti-
